Atualizado
CADILA Healthcare became rocket after USFDA approval
#CADILAHC has received tentative approval from the USFDA to market Carbidopa and Levodopa extended release capsules and stock became rocket and break the level 400 that was strong resistance. Currently stock closed above 400 level.
Showing Bullish result in Technical Parameter:
CCI in overbought zone
RSI crossed above 70
MFI crossed above 80
Stoch in overbought zone
Making higher high since 3 days
DI+ treading above DI-
New Long position
----------------------------------------------------------
Resistance : 410 & 420 & 433
Breakout : 406
LTP : 404.90
Breakdown : 399.75
Support : 390 & 385 & 374
----------------------------------------------------------
Positive & Negative Point:
1) Very Bullish in Daily/Weekly/Monthly chart.
----------------------------------------------------------
(Disclaimer: This is only for educational purpose and paper treading. Learn and take advice from you financial advisor)
Showing Bullish result in Technical Parameter:
CCI in overbought zone
RSI crossed above 70
MFI crossed above 80
Stoch in overbought zone
Making higher high since 3 days
DI+ treading above DI-
New Long position
----------------------------------------------------------
Resistance : 410 & 420 & 433
Breakout : 406
LTP : 404.90
Breakdown : 399.75
Support : 390 & 385 & 374
----------------------------------------------------------
Positive & Negative Point:
1) Very Bullish in Daily/Weekly/Monthly chart.
----------------------------------------------------------
(Disclaimer: This is only for educational purpose and paper treading. Learn and take advice from you financial advisor)
Nota
Hit the target 410 and pull back from level 392Trade fechado: objetivo atingido
Aviso legal
As informações e publicações não se destinam a ser, e não constituem, conselhos ou recomendações financeiras, de investimento, comerciais ou de outro tipo fornecidos ou endossados pela TradingView. Leia mais nos Termos de Uso.
Aviso legal
As informações e publicações não se destinam a ser, e não constituem, conselhos ou recomendações financeiras, de investimento, comerciais ou de outro tipo fornecidos ou endossados pela TradingView. Leia mais nos Termos de Uso.